Journal of Oncology Pharmacy Practice

Papers
(The H4-Index of Journal of Oncology Pharmacy Practice is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class46
A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide34
Cancer patient experience of telephone clinics implemented in light of COVID-1928
Oral silymarin formulation efficacy in management of AC-T protocol induced hepatotoxicity in breast cancer patients: A randomized, triple blind, placebo-controlled clinical trial22
ISOPP Standards for the Safe Handling of Cytotoxics20
Spine eburnation in a metastatic lung cancer patient treated with immunotherapy and radiotherapy. The first case report of bystander effect on bone18
Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations18
International Society of Oncology Pharmacy Practitioners (ISOPP) position statement: Role of the oncology pharmacy team in cancer care16
Impact of clinical pharmacy in oncology and hematology centers: A systematic review15
Ambulatory chemotherapy: Past, present, and future13
Applications and challenges in therapeutic drug monitoring of cancer treatment: A review13
Acquired Hemophilia A following Pfizer-BioNTech SARS CoV-2 mRNA vaccine, successfully treated with prednisolone and rituximab13
Adverse reactions and adherence to capecitabine: A prospective study in patients with gastrointestinal cancer12
Surface contamination with nine antineoplastic drugs in 109 canadian centers; 10 years of a monitoring program12
0.07368803024292